Interestingly, IGHV peptides derived from dendritic cells loaded with therapeutic intravenous Igs [57] share similarities with IGHV peptides derived from self BCR in lymphomas [32,33], suggesting a similar mechanism of degradation. This evidence concerns the gene BCR and lymphoma.